Education
About Us
Working with TipRanks
Follow Us
Evolus, Inc. (EOLS)
NASDAQ:EOLS
EOLS Stock Chart & Stats
$4.24
-$0.47(-4.38%)
At close: 4:00 PM EST
$4.24
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$4.20 - $17.12
Previous CloseN/A
Volume344.54K
Average Volume (3M)1.29M
Market Cap
$291.69M
Enterprise Value$384.26M
Total Cash (Recent Filing)$43.52M
Total Debt (Recent Filing)$154.89M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Mar 11, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding64,819,786
10 Day Avg. Volume1,122,132
30 Day Avg. Volume1,285,271
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)123.99
Price to Sales (P/S)2.57
P/FCF Ratio-35.16
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue1.34
Enterprise Value/Gross Profit2.04
Enterprise Value/Ebitda-13.11
Forecast
1Y Price Target
$14.50Price Target Upside241.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$330.27M
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityCash on hand and access to debt facilities without restrictive covenants provides financial flexibility to sustain operations and fund commercial expansion while management pursues profitability goals.
Market Share ExpansionJeuveau's strengthening market position and Evolus' ability to expand share despite a weak aesthetic market should support revenue resilience and improve competitive positioning as the category recovers.
Product Rollout And BundlingCommercial rollout of new injectable fillers combined with a bundling program that narrows competitors' advantages is likely to help win additional accounts and diversify revenue beyond toxin sales.
Bears Say
Analyst Caution And Sentiment RiskAnalyst caution with maintained Hold views pending a clear market turnaround could weigh on sentiment and limit near-term stock momentum.
Macroeconomic And Consumer HeadwindsContinuing macroeconomic pressures and weaker consumer discretionary spending are constraining demand for aesthetic procedures, which could slow recovery in toxin and filler sales.
Revised Long-term OutlookReduction and recalibration of the company's long-term financial outlook to a smaller addressable market raises uncertainty about future growth and may lower investor expectations.
Evolus News
EOLS FAQ
What was Evolus, Inc.’s price range in the past 12 months?
Evolus, Inc. lowest stock price was $4.20 and its highest was $17.12 in the past 12 months.
What is Evolus, Inc.’s market cap?
Evolus, Inc.’s market cap is $291.69M.
When is Evolus, Inc.’s upcoming earnings report date?
Evolus, Inc.’s upcoming earnings report date is Mar 11, 2026 which is in 27 days.
How were Evolus, Inc.’s earnings last quarter?
Evolus, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.132 earnings per share for the quarter, beating the consensus estimate of -$0.163 by $0.031.
Is Evolus, Inc. overvalued?
According to Wall Street analysts Evolus, Inc.’s price is currently Undervalued.
Does Evolus, Inc. pay dividends?
Evolus, Inc. does not currently pay dividends.
What is Evolus, Inc.’s EPS estimate?
Evolus, Inc.’s EPS estimate is 0.03.
How many shares outstanding does Evolus, Inc. have?
Evolus, Inc. has 64,819,786 shares outstanding.
What happened to Evolus, Inc.’s price movement after its last earnings report?
Evolus, Inc. reported an EPS of -$0.132 in its last earnings report, beating expectations of -$0.163. Following the earnings report the stock price went up 5.433%.
Which hedge fund is a major shareholder of Evolus, Inc.?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (241.98% Upside)
$14.50 (241.98% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 7.0%
Last 30 Days ▲ 15.9%
Last 30 Days ▲ 15.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong growth in consumer engagement, successful product launches, and international expansion, despite facing macroeconomic challenges and tariff uncertainties. Evolus demonstrates resilience and strategic adaptation, positioning for continued growth.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$14.50
▲(241.98% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.24% Insiders
8.85% Mutual Funds
0.44% Other Institutional Investors
76.41% Public Companies and
Individual Investors